Get Live Data

The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO
Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPOView Video
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plant
Stephan Bernstein, CEO of GreenRoc, details the PFS results for the new graphite processing plantView Video

Latest Share Chat

  2. Share Prices
  3. Hemogenyx Share Price
  4. Hemogenyx Share News
  5. IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

Pin to quick picksHemogenyx Share News (HEMO)

Hemogenyx Information

Share Price Information for Hemogenyx (HEMO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.53
Ask: 1.60
Change: 0.00 (0.00%)
Spread: 0.07 (4.575%)
Open: 1.60
High: 1.60
Low: 1.536
Prev. Close: 1.565
HEMO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

IN BRIEF: Hemogenyx To Take Next Steps In Developing Virus Treatment

Mon, 15th Jun 2020 17:54

Hemogenyx Pharmaceuticals PLC - London-based biotechnology firm - Continuing development of Covid-19 medication. Says subsidiary Immugenyx LLC will take cells from blood samples of former Covid-19 sufferers and transplant them into advanced peripheral blood hematopoietic chimera or advanced humanised mice. Hemogenyx says process will allow scientists to recreate virus antibodies.

Current stock price: 5.65 pence

Year-to-date change: up almost threefold from 1.93p on January 2

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
23 Oct 2019 08:41

Hemogenyx Inks USD75,000 Research Deal With Undisclosed Global Firm

Hemogenyx Inks USD75,000 Research Deal With Undisclosed Global Firm

Read more
30 Sep 2019 16:51

Hemogenyx Interim Loss Widens But CDX Antibody Work Progresses

Hemogenyx Interim Loss Widens But CDX Antibody Work Progresses

Read more
19 Oct 2018 08:26

Hemogenyx enters collaboration agreement with Orgenesis

(Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement with cell therapy outfit Orgenesis to further commercialise its humanised-mouse drug model.

Read more
15 Oct 2018 08:32

Hemogenyx inks lupus collaboration with Johnson and Johnson

(Sharecast News) - Biopharmaceutical group Hemogenyx has entered into a collaboration agreement industry giant Johnson and Johnson to develop a model of systemic lupus erythematosus, the most common form of Lupus.

Read more
3 Apr 2018 13:25

Hemogenyx Pharmaceuticals Appoints Marc Feldmann As Executive Chairman

LONDON (Alliance News) - Biotechnology company Hemogenyx Pharmaceuticals PLC said on Tuesday it has appointed Marc Feldmann as executive chairman, with effect next will be who

Read more
123456

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.